Bedaquiline, a new antituberculosis drug, has already been used in> 50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Tuberculosis, caused by the intracellular pathogen Mycobacterium tuberculosis, remains the
world's deadliest infectious disease. Sterilizing chemotherapy requires at least 6 months of …

TO THE EDITOR—Despite considerable advances in the diagnosis and treatment of
tuberculosis, central nervous system tuberculosis is still a devastating and often …

Bedaquiline is recommended for the treatment of all patients with rifampin-resistant
tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular …

Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the
United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis …

Even if major improvements in therapeutic regimens and treatment outcomes have been
progressively achieved, tuberculosis (TB) remains the leading cause of death from a single …

Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging due to high
treatment failure rate and adverse drug events. This study aimed to develop and validate a …

The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-
resistant TB, has strongly motivated the research and development of new anti-TB drugs …

Introduction: Few innovative anti-microbial products have been brought to market in recent
years to combat the global multidrug resistant-tuberculosis (MDR-TB) epidemic …